<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1427">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596085</url>
  </required_header>
  <id_info>
    <org_study_id>NS-VC-CT01-20</org_study_id>
    <nct_id>NCT04596085</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy and Safety of &quot;VIRACIDE&quot; IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)</brief_title>
  <official_title>A Double Blind, Randomized, Placebo Controlled Study to Evaluate Efficacy and Safety of &quot;VIRACIDE&quot; in the Management of Corona Virus Disease 2019 (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Herb, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ProRelix Services LLP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Herb, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blind randomized placebo controlled study will be conducted on 124 subjects,&#xD;
      50 years and older with mild or asymptomatic COVID-19. If symptomatic, symptoms are mild&#xD;
      (cough, weakness, sore throat, low grade fever 38.50С, respiratory rate should not be more&#xD;
      than 22 / min, resting SpO2 &gt;95%, normal highly sensitive C-reactive protein (HS-CRP)&#xD;
      (&lt;10mg/L). There are no signs of dehydration, sepsis or shortness of breath.&#xD;
&#xD;
      The study will be conducted at two centers. There will be a screening visit at Day -4&#xD;
      followed by three visits at the center at Days 1, 7 and 15 and a follow-up visit on Day 28.&#xD;
      All participants will be randomized to receive either ViraCide (investigational product) or&#xD;
      matching placebo. All subjects will receive SOC therapy.&#xD;
&#xD;
      Note: If subject is discharged before Day 15 PI's discretion as per patients health&#xD;
      condition, then assessments scheduled for Day 15 will be carried out on the discharge day (as&#xD;
      far as possible and those not performed will be noted on appropriate CRF page) and Day 15&#xD;
      visit will be done telephonically.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Day 1 Randomization, Vital Signs, Pulse oximetry, AE/SAE, Concomitant Medication, ViraCide/&#xD;
      Placebo treatment start, NEWS scoring; 7-point ordinal scoring Day 7 Physical Examination,&#xD;
      Vital Signs, AE/SAE, Concomitant Medication, ViraCide/ Placebo Compliance check, Pulse&#xD;
      oximetry; NEWS scoring; 7-point ordinal scoring.&#xD;
&#xD;
      (Note: If the subject is discharged on this day as per PI's discretion and patient's health&#xD;
      condition then assessment scheduled for day 15 will be carried out on discharge day).&#xD;
&#xD;
      Day 15 Physical Examination, Vital Signs, AE/SAE, Concomitant Medication, ViraCide/ Placebo&#xD;
      treatment end, RT-PCR for Sars- Co-V2, Hs-CRP, Safety Lab Tests, Pulse oximetry; NEWS&#xD;
      scoring; 7-point ordinal scoring, ViraCide/ Placebo Compliance check, Lab assessment&#xD;
      including urine analysis Day 28&#xD;
&#xD;
      Phone call follow up for time :&#xD;
&#xD;
        -  until negative RT-PCR for Sars-Co- V2, COVID-19 related mortality,&#xD;
&#xD;
        -  development of any COVID-19 symptom,&#xD;
&#xD;
        -  development of any worsening of comorbid condition;&#xD;
&#xD;
        -  Development of new AE/SAE; Resolution status of previous AE/SAEs&#xD;
&#xD;
      Note: If subject is discharged before Day 15on PI's discretion as per patients health&#xD;
      condition, then assessments scheduled for Day 15 will be carried out on the discharge day (as&#xD;
      far as possible and those not performed will be noted on appropriate CRF page) and Day 15&#xD;
      visit will be done telephonically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double Blind, Randomized, Placebo Controlled</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Randomized, Double - Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>NEWS Score</measure>
    <time_frame>First treatment date up to day 15</time_frame>
    <description>Time to Clinical Improvement (TTCI) using NEWS Score23 [Time Frame:First treatment date up to discharge day (PI's discretion as per patient's health condition)]&#xD;
The median time in days from the start of treatment with the study drug / placebo to the persistent achievement of all of the following criteria:&#xD;
i. Stopping a fever (which is defined as a decrease in axillary temperature below 37 ° C without the use of antipyretic drugs); ii. Respiratory rate &lt;22 /min; iii. Oxygen saturation (SPO2) &gt; 95% when breathing in atmospheric air. Measured using pulse oximetry iv. Systolic blood pressure ≤200mmHg v. Pulse rate 51-90beats/minute vi. Is conscious and alert</description>
  </primary_outcome>
  <primary_outcome>
    <measure>7-point ordinal scale</measure>
    <time_frame>First treatment date up to day 15</time_frame>
    <description>TTIC using 7-point ordinal scale3 [Time Frame: First treatment date up to discharge day (PI's discretion as per patients health condition)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of progression on NEWS score</measure>
    <time_frame>First treatment date up to 15 days</time_frame>
    <description>Rate of progression to severe/critical COVID-19 disease based on NEWS score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of progression on 7 point ordinal score</measure>
    <time_frame>First treatment date up to 28days</time_frame>
    <description>Rate of progression to severe/critical COVID-19 disease based on 7-point</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to COVID-19 nucleic acid testing</measure>
    <time_frame>Time Frame: First treatment date up to 28days</time_frame>
    <description>Time to COVID-19 nucleic acid testing negativity in oropharyngeal/nasal swab)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU admissions</measure>
    <time_frame>Time Frame: 28days</time_frame>
    <description>Incidence of ICU admissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival rate</measure>
    <time_frame>Time Frame: 28 days</time_frame>
    <description>Subject survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mechanical ventilation</measure>
    <time_frame>Time Frame: First treatment date up to 28 days]</time_frame>
    <description>Incidence of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to COVID-19 nucleic acid testing</measure>
    <time_frame>Time Frame: Days 1, 7, 15</time_frame>
    <description>Time to COVID-19 nucleic acid testing negativity in oropharyngeal/nasal swab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessmentofcomorbidcondition</measure>
    <time_frame>Time Frame: First treatment date up to 28days]</time_frame>
    <description>Change in clinical or laboratory assessment of comorbid condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worsening comorbid condition</measure>
    <time_frame>Time Frame: First treatment date up to 28days]</time_frame>
    <description>Percent of participants with worsening comorbid condition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Investigational product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Experimental, Investigational Product Ingredient : ViraCide Dosage form softgels . Fequency: 3 soft gels, two times every day after breakfast and dinner . Duration: 14 days+ SOC Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ingredient, Placebo Ingredient Starch softgels. Frequency: 3 soft gels, two times everyday after breakfast and dinner . Duration:14 days + SOC Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Investigational Product - ViraCide</intervention_name>
    <description>Viracide</description>
    <arm_group_label>Investigational product</arm_group_label>
    <other_name>Investigational Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo - Starch Powder Soft gels</intervention_name>
    <description>Starch Powder Soft gels</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 50 years or older&#xD;
&#xD;
          2. Both male and female subjects will be included&#xD;
&#xD;
          3. Positive oropharyngeal/nasal swab RT-PCR for Sars-Co- V2. Diagnosed not more than 2&#xD;
             days ago(diagnosis&#xD;
&#xD;
             ≤2days).&#xD;
&#xD;
          4. Either asymptomatic or have mild symptoms. Onset of symptoms within no more than 4&#xD;
             days If symptomatic, symptoms are mild (cough, weakness, sore throat, low grade fever&#xD;
             38.50С, respiratory rate should not be more than 22 / min, resting SpO2 &gt;95%, normal&#xD;
             highly sensitive C-reactive protein (HS-CRP) (&lt;10mg/L). There are no signs of&#xD;
             dehydration, sepsis or shortness of breath.&#xD;
&#xD;
          5. Chronic stable medical conditions: diabetes mellitus, or hypertension, or chronic&#xD;
             heart disease. Under treatment and controlled by medication&#xD;
&#xD;
          6. Signed informed consent/or consent given through text message, WhatsApp ore-mail.&#xD;
&#xD;
          7. Ability to understand the requirements of the Research Protocol and follow the&#xD;
             research procedures.&#xD;
&#xD;
          8. Subject should be willing to be managed in isolation wards&#xD;
&#xD;
          9. Negative pregnancy test (for female participants)&#xD;
&#xD;
         10. Adequate contraception for study duration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Less than 50years&#xD;
&#xD;
          2. With severe COVID-19 symptoms requiring immediate hospitalization&#xD;
&#xD;
          3. Investigator considers the subject unsuitable for ViraCide&#xD;
&#xD;
          4. History of symptoms of more than 4days&#xD;
&#xD;
          5. COVID-19 diagnosed &gt;2 days ago using oropharyngeal/nasal swab RT-PCR forSars-Co-V2&#xD;
&#xD;
          6. History of cardiopulmonary resuscitation&#xD;
&#xD;
          7. Subjects having history of organ failure or conditions requiring ICU monitoring and&#xD;
             treatment, such as severe liver disease, severe renal dysfunction, upper&#xD;
             gastrointestinal hemorrhage, disseminated intravascular coagulation or any other&#xD;
             condition that in the PI&quot;s opinion makes the subject unfit to participate&#xD;
&#xD;
          8. Respiratory failure, ARDS or need of mechanical ventilation&#xD;
&#xD;
          9. History of acute exacerbation of comorbidity like heart failure, diabetic&#xD;
             ketoacidosis, myocardial infection, major cardiac rhythm disorder or any other&#xD;
             condition that in the PI&quot;s opinion makes the subject unfit to participate&#xD;
&#xD;
         10. History of or current hepatic failure or severely compromised liver function, or renal&#xD;
             failure or having chronic kidney disease or acute renal failure&#xD;
&#xD;
         11. History of or currently receiving treatment for an endocrine disorder like&#xD;
             hypothyroidism, hyperthyroidism that is likely to affect the basal heart rate.&#xD;
&#xD;
         12. History of or currently under treatment for asthma [exception: patients with history&#xD;
             of asthma, not on medications/inhalers/nebulizers for at least 6 months before study&#xD;
             start), COPD, bronchiectasis, asbestosis and other such chronic lung conditions that&#xD;
             can compromise SpO2 and RR.&#xD;
&#xD;
         13. HIV, HBsAg, HCV positive&#xD;
&#xD;
         14. Any condition causing immunodeficiency&#xD;
&#xD;
         15. Systemic connective tissue disease or any autoimmune disease that is likely to affect&#xD;
             HS-CRP levels&#xD;
&#xD;
         16. History of epilepsy/epileptic fit/convulsions in last 6 months or currently on&#xD;
             treatment for it&#xD;
&#xD;
         17. History of or currently having malignancy and being treated for it. (exception:&#xD;
             histologically confirmed and cured carcinoma in situ)&#xD;
&#xD;
         18. Hypersensitivity reaction to Study drug/placebo&#xD;
&#xD;
         19. Any psychiatric issue for which the subject is currently undergoing treatment&#xD;
&#xD;
         20. Any history of drug/alcohol dependence within 30 days of screening or current&#xD;
             drug/alcohol dependence&#xD;
&#xD;
         21. Inability to understand the requirements of the Research Protocol and follow the&#xD;
             research procedures.&#xD;
&#xD;
         22. Pregnant or lactating;&#xD;
&#xD;
         23. Not willing to use adequate contraception during study duration&#xD;
&#xD;
         24. Participation in any other clinical study less than 3months before the start of the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr.Ninad Naik, MD(Ayurveda)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gunjkar Multispeciality Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. A Gopal Rao, MD(Med)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Government medical college and Government general hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr.Mahir Abduldaim</last_name>
    <phone>08847769291</phone>
    <email>info@prorelixresearch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sohal Pendse</last_name>
    <phone>9890096725</phone>
    <email>s.pendse@prorelixresearch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of General medicine/ clinical research. Government medical college and Government general hospital</name>
      <address>
        <city>Srikakulam</city>
        <state>Andhra Pradesh</state>
        <zip>532001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. A Gopal Rao, MD Medcine</last_name>
      <phone>9440122790</phone>
      <email>drgopalraoa@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Muralidhar Gudla</last_name>
      <phone>+91 9912320517</phone>
      <email>muralidhargudla@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. A Gopal Rao, MD(Med)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gunjkar Multispeciality Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411019</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sohal Pendse</last_name>
      <phone>9890096725</phone>
      <email>s.pendse@prorelixresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Niranjan Andhalkar</last_name>
      <phone>8847769291</phone>
      <email>n.andhalkar@prorelixresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dr Ninad Naik, MD(Ayurveda)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronavirus, (SARS-CoV-2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

